Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
MERRIMACK PHARM (NQ: MACK)
5.210 USD  -0.060 (-1.14%)
Streaming Delayed Price  /  Updated: 1:11 PM EDT, May 22, 2013  /  Add to My Watchlist      
View: Quote News
All news about MERRIMACK PHARM
 
< Previous 1 2 3 Next >
Singh's TPG-Axon Shows New Stake in Agilent (A), Express Scripts (ESRX), FMC (FMC) (more...)
May 15, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8341315 for the full story. Read More
from StreetInsider.com News Articles
Merrimack Reports First Quarter 2013 Financial Results
May 13, 2013
MM-398 Phase 3 (NAPOLI-1) Top Line Results and Several MM-121 Phase 2 Top Line Results Expected in Second Half of 2013 Read More
from GlobeNewswire News Releases
Earnings Scheduled For May 13, 2013
May 13, 2013
China Green Agriculture, Inc. (NYSE: CGA ) is expected to report its Q3 earnings at $0.45 per share on revenue of $84.80 million. China Yuchai International Limited (NYSE: CYD ) is projected to report... Read More
category Earnings , Benzinga , VELT , and 39 more.
from Latest Articles from Benzinga.com
Four Below Shares Add to After-Hours (PAL, LNCO, MACK, VCRA)
May 06, 2013
New York, NY -- (SBWIRE) -- 05/06/2013 -- North American Palladium Ltd. (NYSEMKT:PAL) revealed that its first-quarter net reduction increased to C$2.8 thousand or C$0.02 per discuss from net lack of... Read More
from SBWire - Latest Press Releases
Stocks Hitting 52-Week Lows
May 06, 2013
Merrimack Pharmaceuticals (NASDAQ: MACK ) shares touched a new 52-week low of $4.145. Merrimack' trailing-twelve-month profit margin is -186.58%. Ecopetrol SA (NYSE: EC ) shares reached a new 52-week... Read More
category Benzinga , EBR , 52/Week Lows , and 7 more.
from Latest Articles from Benzinga.com
Merrimack to Present at Multiple Investor Conferences This Spring
May 02, 2013
from GlobeNewswire News Releases
Merrimack Pharmaceuticals Announces Timing of First Quarter 2013 Investor Conference Call
April 30, 2013
from GlobeNewswire News Releases
Merrimack Pharmaceuticals Completes Enrollment of Second Cohort in Phase 2 Study of MM-121 in Non-Small Cell Lung Cancer
April 29, 2013
from GlobeNewswire News Releases
Merrimack Pharmaceuticals Getting Very Oversold (MACK)
April 24, 2013
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... Read More
category Stocks
from Market News Video
8 Biotechnology Stocks to Sell Now
April 17, 2013
 Read More
category NASDAQ:TSRX , NASDAQ:ACHN , NASDAQ:EXEL , and 6 more.
from InvestorPlace - Latest Headlines
Merrimack Pharmaceuticals (MACK) Completes Enrollment in Phase 2 Study of MM-121 in HER2-Negative Breast Cancer
April 15, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8251886 for the full story. Read More
from StreetInsider.com News Articles
Merrimack Pharmaceuticals Completes Enrollment of One Cohort in Neoadjuvant Phase 2 Study of MM-121 in HER2-Negative Breast Cancer
April 15, 2013
from GlobeNewswire News Releases
Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
April 10, 2013
Merrimack Pharmaceuticals (NASDAQ: MACK ) today announced preclinical study results showing that the novel bispecific therapy MM-111 restored tumor sensitivity to the chemotherapy agent, paclitaxel,... Read More
category Benzinga , News , FDA , and 1 more.
from Latest Articles from Benzinga.com
Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
April 10, 2013
Study Presented at AACR 2013 Examines Bispecific Antibody in Combination with Paclitaxel and Trastuzumab Read More
from PR Newswire
Merrimack Pharmaceuticals' Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
April 08, 2013
Preclinical Results Presented at AACR 2013 Examines ErbB3-Targeted Antibody for the Treatment of ER+ Breast Cancer Read More
from PR Newswire
Merrimack Pharmaceuticals Announces Webcast of Inaugural Research & Development Day
April 05, 2013
from GlobeNewswire News Releases
Streetinsider.com Pre-Market Movers 04/04: (ALU) (PSDV) (NAVB) Higher; (MACK) (CPWR) (LSE) Lower
April 04, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8233428 for the full story. Read More
from StreetInsider.com News Articles
Merrimack lung cancer drug fails goal in one mid-stage trial group
April 04, 2013
April 4 (Reuters) - Merrimack Pharmaceuticals Inc said one of three patient groups in a mid-stage trial of its experimental lung cancer drug failed to meet the main goal of improving survival rates... Read More
category companyNews
from Reuters: Company News
Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
April 04, 2013
from PR Newswire
Merrimack Pharmaceuticals To Present Preclinical Research On Five Novel Cancer Therapies
April 02, 2013
Research Presented at AACR 2013 to Address Data on Safety and Activity Profiles in Preclinical Models Read More
from PR Newswire
Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Paclitaxel in Patients With Platinum-Resistant or Refractory Advanced Ovarian Cancers
March 18, 2013
from GlobeNewswire News Releases
Samsung’s New Phone & Bank Stress Tests Head Thursday’s Must Know News
March 14, 2013
category Market/Outlook , Wall/Street/Preview , Market/Outlook/2013/Q1
from Wall Street Greek
Merrimack Pharm (MACK) Posts Wider than Expected Q4 Loss
March 14, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8184380 for the full story. Read More
from StreetInsider.com News Articles
Merrimack Reports Fourth Quarter and Full Year 2012 Financial Results
March 14, 2013
from GlobeNewswire News Releases
Most Active NASDAQ Stocks: Francesca's Holdings Corp, Acorda Therapeutics Inc, Merrimack Pharmaceuticals Inc, EZchip Semiconductor Ltd
March 06, 2013
Lakeway, TX -- (SBWIRE) -- 03/06/2013 -- vbtrendreport.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the... Read More
from SBWire - Latest Press Releases
Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry's Success in 2012
March 06, 2013
RDInvesting Provides Stocks Research on BioTime and Merrimack Pharmaceuticals Read More
from Marketwired News Releases
Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2012 Investor Conference Call
February 27, 2013
from GlobeNewswire News Releases
Merrimack to Present at the Cowen and Company 33rd Annual Health Care Conference
February 25, 2013
from GlobeNewswire News Releases
Merrimack to Participate in Pancreatic Cancer Panel at the 2013 BIO CEO & Investor Conference
February 07, 2013
from GlobeNewswire News Releases
Merrimack Pharma (MACK) Files $200M Mixed Shelf
February 01, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8051184 for the full story. Read More
from StreetInsider.com News Articles
< Previous 1 2 3 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here